IL-17 Inhibition vs IL-23 Inhibition for Psoriatic Arthritis: An Ongoing Debate
Canadian Rheumatology Today · 2025
DOI: 10.58931/crt.2025.2262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Rheumatology Today, 2025. Verfasst von Pankti Mehta und 1 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The interleukin-17 (IL-17) and interleukin-23 (IL-23) pathways play a central role in the pathogenesis of psoriatic disease (PsD). This review outlines the immunobiology of these cytokine pathways and summarizes the current evidence on the efficacy and safety of IL-17 and IL-23 inhibitors across PsD domains, including peripheral arthritis, axial arthritis, enthesitis, dactylitis, psoriasis, and inflammatory bowel disease (IBD). IL-17 inhibitors, which target the effector cytokines IL-17A, IL-17F, or their receptors, have demonstrated robust efficacy in psoriasis, peripheral arthritis, and axial disease. IL-23 inhibitors act upstream by targeting the p19 subunit of IL-23 and show comparable efficacy in peripheral arthritis and psoriasis, though evidence for efficacy in axial disease remains limited. While IL-17 inhibitors carry a risk of IBD exacerbation, IL-23 inhibitors are considered therapeutic options for patients with coexisting IBD. In addition, radiographic progression appears better suppressed by IL-17 inhibitors, although emerging data suggest that IL-23 blockade may offer delayed benefits. Both IL-17 and IL-23 drug classes exhibit favourable safety profiles, with clinical trials suggesting slightly better tolerability for IL-23 inhibitors. Future directions include head-to-head comparisons, biomarker-guided treatment selection, and trials assessing long-term structural outcomes. Understanding the tissue- and cell-specific effects of inhibiting these cytokine pathways is key to optimizing therapy in PsD.
Zitieren
APA
Mehta, P., & Chandran, V. (2025). IL-17 Inhibition vs IL-23 Inhibition for Psoriatic Arthritis: An Ongoing Debate. Canadian Rheumatology Today. https://doi.org/10.58931/crt.2025.2262
Vancouver
Mehta P, Chandran V. IL-17 Inhibition vs IL-23 Inhibition for Psoriatic Arthritis: An Ongoing Debate. Canadian Rheumatology Today. 2025. doi:10.58931/crt.2025.2262
BibTeX
@article{Mehta2025,
author = {Mehta, Pankti and Chandran, Vinod},
title = {IL-17 Inhibition vs IL-23 Inhibition for Psoriatic Arthritis: An Ongoing Debate},
journal = {Canadian Rheumatology Today},
year = {2025},
doi = {10.58931/crt.2025.2262}
}
EUVIMED